Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors Hematology
Biosimilars
Global Health
Abbreviations
NIS793 - TGFẞ1 inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
Target Patients
Read-out Milestone(s)
NCT04935359 (CNIS793B12301)
Pancreatic cancer, 1st line
Phase 3
490
Safety run-in part: Percentage of participants with dose limiting toxicities (DLTs)
during the first cycle (4 weeks) of treatment
Randomized part: Overall survival (OS)
Arm 1: Experimental: Safety run-in part: NIS793+gemcitabine+nab-paclitaxel
In the safety run-in part, participants will receive a combination of NIS793,
gemcitabine and nab-paclitaxel
Arm 2: Experimental: Randomized part: NIS793+gemcitabine+nab-paclitaxel
Participants will receive a combination of NIS793, gemcitabine and nab-paclitaxel
Arm 3: Placebo Comparator: Randomized part: placebo+gemcitabine+nab-
paclitaxel
Participants will receive a combination of placebo, gemcitabine and nab-paclitaxel
Patients with Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC), first line
treatment
Primary 2025
Publication
TBD
117 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation